{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:34Z","timestamp":1792039594172,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032792","name":"AstraZeneca \u00d6sterreich","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109639","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:45:31Z","timestamp":1790783131000},"page":"109639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-5205","authenticated-orcid":false,"given":"Daniel","family":"Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3204-8943","authenticated-orcid":false,"given":"Anna","family":"Lang-St\u00f6berl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Fabikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-7982","authenticated-orcid":false,"given":"Julie","family":"Krainer-Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7322-7092","authenticated-orcid":false,"given":"Oliver","family":"Illini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1989-0456","authenticated-orcid":false,"given":"Leyla","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0412-0947","authenticated-orcid":false,"given":"Nino","family":"M\u00fcser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Weinlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania Mikaela","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-0271","authenticated-orcid":false,"given":"Georg-Christian","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Kathrin","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robab","family":"Breyer-Kohansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arschang","family":"Valipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109639_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clinicians."},{"key":"10.1016\/j.lungcan.2026.109639_b0010","unstructured":"STATISTIK AUSTRIA, \u00d6sterreichisches Krebsregister (Stand 10.01.2025) und Todesursachenstatistik. Anzahl maligner invasiver Tumoren inkl. DCO-F\u00e4lle. Vom 16.01.2025. https:\/\/www.statistik.at\/statistiken\/bevoelkerung-und-soziales\/gesundheit\/krebserkrankungen. Accessed October 1, 2025."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109639_b0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109639_b0020","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jtho.2020.10.158","article-title":"Lung Cancer in Austria","volume":"16","author":"Pirker","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109639_b0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2023.05.008","article-title":"Advancements in small cell lung cancer","volume":"93","author":"Lee","year":"2023","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109639_b0030","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41571-024-00914-x","article-title":"Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer","volume":"21","author":"Sen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109639_b0035","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109639_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109639_b0045","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109639_b0050","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109639_b0055","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or Placebo Plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"JCO"},{"issue":"34","key":"10.1016\/j.lungcan.2026.109639_b0060","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1200\/JCO.2006.06.5821","article-title":"Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer","volume":"24","author":"O\u2019Brien","year":"2006","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2026.109639_b0065","doi-asserted-by":"crossref","unstructured":"Lang-St\u00f6berl A, Fabikan H, Hochmair M, et al. The Landsteiner lung cancer research platform (LALUCA): Objectives, methodology and implementation of a real-world clinical lung cancer registry. Wien Klin Wochenschr. Published online April 23, 2024. doi:10.1007\/s00508-024-02351-3.","DOI":"10.1007\/s00508-024-02351-3"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109639_b0070","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109639_b0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jtho.2024.01.019","article-title":"The international association for the study of lung cancer staging project for lung cancer: proposals for the revision of the M descriptors in the forthcoming ninth edition of the TNM classification for lung cancer","volume":"19","author":"Fong","year":"2024","journal-title":"J. Thoracic Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109639_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109639_b0085","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Accessed October 25, 2024. https:\/\/www.r-project.org\/."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109639_b0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/cancers18020278","article-title":"Clinical impact of EGFR mutation subtypes on treatment outcomes in advanced non-small cell lung cancer: an austrian real-world study","volume":"18","author":"Braschel","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2026.109639_b0095","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221103206","article-title":"Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program","volume":"14","author":"Illini","year":"2022","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.lungcan.2026.109639_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107997","article-title":"Neoadjuvant therapy in early-stage non-small cell lung cancer: a real-world analysis","volume":"198","author":"Ay","year":"2024","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109639_b0105","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.3390\/cancers17132190","article-title":"The efficacy of first-line pembrolizumab monotherapy in patients with metastatic NSCLC Aged \u226570 years with high PD-L1 (TPS \u2265 50%) expression: a multicenter real-world study","volume":"17","author":"Markovi\u0107","year":"2025","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.lungcan.2026.109639_b0110","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109639_b0115","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109639_b0120","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cllc.2025.07.003","article-title":"The Italian Mauris phase IIIb trial of atezolizumab plus carboplatin and etoposide for patients with newly diagnosed extensive-stage small cell lung cancer: 3-year end-of-study results","volume":"26","author":"Morgillo","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109639_b0125","doi-asserted-by":"crossref","first-page":"S1246","DOI":"10.1016\/j.annonc.2022.07.1626","volume":"33","author":"Garcia Campelo","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109639_b0130","unstructured":"NCCN Guidelines. NCCN Guidelines: Small Cell Lung Cancer. Accessed September 4, 20https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1462."},{"issue":"10495","key":"10.1016\/j.lungcan.2026.109639_b0135","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109639_b0140","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0098","article-title":"Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer","volume":"12","author":"Hanvesakul","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"10.1016\/j.lungcan.2026.109639_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109639_b0150","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/imj.16348","article-title":"Lurbinectedin in small cell lung cancer: real\u2010world experience of a multicentre national early access programme","volume":"54","author":"Alexander","year":"2024","journal-title":"Intern. Med. J."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109639_b0155","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/j.jtho.2024.09.1412","article-title":"P1.13B.01 lurbinectedin vs. platinum rechallenge in extensive stage small cell lung cancer after platinum doublet, a multicenter retrospective study","volume":"19","author":"Libre","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109639_b0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cllc.2026.02.007","article-title":"Brief report: real-world outcomes of lurbinectedin in veterans with small cell lung cancer","volume":"27","author":"Curt","year":"2026","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109639_b0165","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109639_b0170","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.lungcan.2020.03.024","article-title":"Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) \u2013 a decision-making analysis amongst European lung cancer experts","volume":"146","author":"Fr\u00fch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109639_b0175","unstructured":"Pr\u00e4vention, Diagnostik, Therapie Und Nachsorge Des Lungenkarzinoms. 2025."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109639_b0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"Von Pawel","year":"1999","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2026.109639_b0185","doi-asserted-by":"crossref","unstructured":"Rost M, Fischer R, Reck M, et al. Treatment patterns, outcome and QoL of ES-SCLC patients receiving third-line therapy \u2013 Data from the German CRISP Registry (AIO-TRK-0315): A Brief Report. JTO Clinical and Research Reports. Published online January 24, 2026:100959. doi:10.1016\/j.jtocrr.2026.100959.","DOI":"10.1016\/j.jtocrr.2026.100959"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109639_b0190","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(20)30461-7","article-title":"Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial","volume":"21","author":"Baize","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109639_b0195","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109639_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2026.109390","article-title":"Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer","volume":"216","author":"Cooper","year":"2026","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109639_b0205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cllc.2025.11.018","article-title":"Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: real-world insights into step-up dosing and prophylactic tocilizumab use","volume":"27","author":"Joshi","year":"2026","journal-title":"Clin. Lung Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2026.109639_b0210","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109639_b0215","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1200\/JCO.2025.43.16_suppl.8088","article-title":"Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer","volume":"43","author":"Parma","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2026.109639_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2026.116686","article-title":"Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice","volume":"238","author":"Blocker","year":"2026","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109639_b0225","first-page":"209","article-title":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","author":"Andreas","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226007002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:07:34Z","timestamp":1792037254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226007002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":45,"alternative-id":["S0169500226007002"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109639","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109639"}}